Mini-Review Article

Xing Liu, Bin Shi*

Progress in research on the role of fibrinogen in lung cancer

https://doi.org/10.1515/biol-2020-0035
received August 18, 2019; accepted March 17, 2020

Abstract: Lung cancer is one of the most prevalent malignancies worldwide. Local recurrence and distant metastasis remain the major causes of treatment failure. It has been recognized that the process of tumor growth and metastasis involves multiple interactions between tumor and host. Various biomarkers have been used for predicting tumor recurrence, metastasis, and prognosis in patients with lung cancer. However, these biomarkers are still controversial and require further validation. The relationship between malignancy and coagulation system disorders has been explored for more than a century. Fibrinogen is the most abundant plasma coagulation factor synthesized mainly by hepatic cells. Increased plasma fibrinogen levels were observed in various carcinomas such as gastric cancer, colon cancer, and pancreatic cancer. Recent studies have also investigated the role of fibrinogen in patients with lung cancer. This review aimed to address the role of fibrinogen in lung cancer.

Keywords: fibrinogen, cancer biomarkers, lung cancer

1 Introduction

Lung cancer is a leading cause of cancer death around the world. The 5-year survival rate is only 15%, although various therapies are adopted [1]. Local recurrence and distant metastasis are the main reasons for treatment failure. Numerous factors including carcinoembryonic antigen, neuron-specific enolase, cytokeratin-19 fragments (CYFRA 21-1), and D-dimer for early diagnosis of distant metastasis, tumor recurrence, and prognosis in

patients with lung cancer have been intensively identified [2,3]. However, the majority of these conventional indicators are still unsatisfactory.

Tumor-induced coagulation system disorders are commonly implicated in patients with malignancies. Fibrinogen is an essential constituent of the coagulation system. It is mainly synthesized in the liver and released into the circulation in response to systemic inflammation and malignancy. An increasing body of evidence has indicated the association between fibrinogen and tumor clinical stage, angiogenesis, metastatic spread, and response to therapy in patients with cancer [4,5]. The clinical value of fibrinogen in patients with lung cancer has also been investigated previously. To further understand its role, we reviewed fibrinogen estimation in patients with lung cancer.

2 Fibrinogen expression in lung cancer

High levels of fibrinogen have been observed in patients with lung cancer (Table 1). Kim et al. [9] reported that serum fibrinogen levels were increased in about 55.2% of patients with advanced non-small cell lung cancer (NSCLC), and its concentration may be higher in patients with squamous cell carcinoma than in patients with adenocarcinoma (4.5 ± 0.13 g/L vs 3.6 ± 0.28 g/L, p = 0.008) [4]. Elevated serum fibrinogen concentration can change blood viscosity, rheology, and endothelial function, which may facilitate microthrombosis in the pulmonary capillaries and make patients vulnerable to inflammation and ischemia [10,11]. Therefore, detection of serum fibrinogen levels may reflect lung tissue destruction. As previously reported, mean plasma fibrinogen levels were associated with the pathological T stage but not with the pathological N stage [4]. However, other investigators found that there were no statistically significant differences in fibrinogen levels according to the TNM stage [9].

* Corresponding author: Bin Shi, Department of Respiratory Medicine, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian 223800, Jiangsu, China, e-mail: 18115222585@163.com

Xing Liu: Department of Respiratory Medicine, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian 223800, Jiangsu, China
Table 1: The expression of fibrinogen in lung cancer

| Histology (n)                  | n  | Parameters evaluated | Main outcome of the study                                                                 | Ref. |
|-------------------------------|----|----------------------|-----------------------------------------------------------------------------------------|------|
| AC (18), SQ (69), LCC (2),    | 93 | Fibrinogen           | Elevated plasma fibrinogen level was positively correlated with increasing tumor size,   | [4]  |
| other NSCLC (3)               |    |                      | advanced pathological T stage, and SCC.                                                  |      |
| NS                            | 55 | Fibrinogen and FDP   | Serum fibrinogen and FDP levels were elevated in lung cancer patients with metastases.   | [6]  |
| AC (165), SQ (106), LCC (22), | 339| Fibrinogen           | Increased serum fibrinogen levels were associated with advanced SCC or LCC.              | [7]  |
| SCC (46)                      |    |                      | High pre- and postoperative fibrinogen levels in patients with NSCLC were associated with| [8]  |
| AC (114), SQ (61), other      | 184| Fibrinogen           | lymph node involvement of the tumor and pathologic stages.                               |      |
| NSCLC (9)                     |    |                      |                                                                                         |      |

AC, adenocarcinoma; FDP, fibrinogen degradation product; LCC, large cell carcinoma; n, number of specimens; NS, not specified; NSCLC, non-small cell lung cancer; SCC, small cell carcinoma; SQ, squamous cell lung cancer.

Guan et al. [12] explored the relationship between fibrinogen and epidermal growth factor receptor (EGFR) mutation status in patients with NSCLC; they found that plasma fibrinogen levels were distinctly higher in patients with wild-type EGFR gene than in patients with EGFR mutations (3.57 g/L vs 2.95 g/L, \( p < 0.001 \)). This shows that fibrinogen may assist in predicting EGFR mutation status in patients with NSCLC. However, additional studies are required to fully illustrate the molecular mechanism between fibrinogen and EGFR gene mutation status.

### 3 Role of fibrinogen in tumor progression

Cancer-related coagulation disorders have been thought to be responsible for the tumor cell growth, invasion, and distant metastasis. Recently, a series of experiments have shown the significance of fibrinogen in the pathogenesis of the cancer process [13–15]. As tumor cells dissociate from the primary focus into the circulation, fibrinogen can serve as a scaffold to bind tumor cells and platelets [15], which in turn contributes to tumor cell adherence to the distant organ and promotes tumor angiogenesis. Furthermore, fibrinogen has been implicated in the formation of tumor stroma, which provides gas exchange and nutrient for rapidly proliferating tumor cells.

Palumbo et al. [16] demonstrated that the deficiency of fibrinogen strongly reduced the spontaneous metastatic potential through both hematogenous and lymphatic routes but has no influences on the time required for the formation of palpable tumors, angiogenesis, and overall tumor architecture. Similarly, Palumbo et al. [17] also found that fibrinogen deficiency dramatically reduced the incidence of pulmonary metastases in fibrinogen-deficient transgenic mice. However, additional experiments are required to fully illustrate the relationship between fibrinogen and tumor metastasis.

As an extracellular protein matrix, fibrinogen not only promotes the migration of tumor cells but also protects tumor cells from the innate immune surveillance systems [14]. Zheng et al. [18] reported that fibrinogen can protect tumor cells from natural killer (NK) cell-mediated cytotoxicity by accumulating and forming dense fibrin layers around tumor cells. Gropp et al. [6] also found that fibrinogen split products can suppress immune reactions. Therefore, we can make the treatment more effective for patients with cancer by reducing the activity of the coagulation system.

### 4 Fibrinogen and the prognosis of lung cancer

The potential predictive value of fibrinogen for prognosis in patients with lung cancer has been reported in the previous investigations (Table 2). A significant relationship between initial response to chemotherapy and decreased fibrinogen levels was found in patients with elevated plasma levels of fibrinogen [5]. Jones et al. [4] reported that high fibrinogen values (plasma fibrinogen >5 g/L) were related to incomplete resection in patients with NSCLC. A retrospective analysis explored the correlation between preoperative serum fibrinogen levels and postoperative pulmonary complications (PPCs) in patients who underwent lung cancer resection.
They found that high levels of preoperative serum fibrinogen (>400 mg/dL) were associated with the increased risk of PPCs, and it was an independent predictor regardless of sex and smoking status [30]. Jiang et al. [8] evaluated the value of pre- and postoperative plasma fibrinogen levels in predicting tumor recurrence and metastasis in 184 patients with I–IIIA NSCLC, who underwent radical surgery. They found a correlation between high pre- and postoperative plasma fibrinogen levels and tumor recurrence. This indicated that plasma fibrinogen levels may be used to predict tumor metastasis and recurrence for lung cancer patients who underwent surgery.

Several investigators reported that patients with higher plasma fibrinogen levels tend to have poor progression-free survival (PFS) and overall survival (OS) [19,21]. A meta-analysis suggested that the level of plasma fibrinogen >400 mg/dL could be a promising indicator for worse OS in patients with lung cancer [31]. Ying et al. [27] explored the usefulness of the albumin-to-fibrinogen ratio (AFR) in patients with advanced NSCLC; they found that the PFS and OS in the high AFR group (>8.02) were markedly improved compared with those in the low AFR group. Therefore, fibrinogen may serve as a candidate biomarker for disease monitoring and prognostic evaluation in patients with lung cancer.

### 5 Fibrinogen and the treatment of lung cancer

It is increasingly recognized that the variation in fibrinogen concentration is associated with the treatment of malignancies. Zhu et al. [21] showed that fibrinogen levels decreased after one and two chemotherapy cycles in patients with small cell lung cancer (SCLC), and the degree of decline was associated with the treatment response. Morano et al. [32] also revealed that serum fibrinogen levels were significantly reduced after 4 weeks of pulmonary rehabilitation in patients with lung cancer.

Some investigators have focused on the therapeutic strategies for controlling tumor metastasis by improving the hypercoagulable status. As reported in the previous studies, the inhibition of tissue factor, factor Xa, and thrombin significantly reduced the experimental hematogenous metastasis [33]. Palumbo et al. [17] also found that thrombin inhibitor substantially diminished the metastatic potential of circulating tumor cells in fibrinogen-deficient mice but had no apparent influence on tumor cell proliferation in vitro. Therefore, anticoagulation therapy may prolong the survival time of patients with cancer.
6 Conclusion
The treatment and prognosis of cancer depend on the tumor stage, presence of comorbidities, and other factors. Various biomarkers and their combinations for tumor progression and prognosis have been explored. The coagulation abnormality in patients with cancer has been recognized for decades. Considerable attention has been paid to the relationship between the progression of lung cancer and fibrinogen. As we have mentioned above, fibrinogen is a valuable biomarker to predict tumor status, EGFR mutation status, and clinical outcome above, thereby making it important in lung cancer and is associated with tumor progression and metastasis. As a noninvasive method, measurement of fibrinogen is simple, economical, and less traumatic in clinical practice. Further studies are needed to elucidate the relationship between fibrinogen and lung cancer biology.

Conflicts of interest: The authors state no conflict of interest.

References
[1] Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran Jr WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.
[2] Cho HI, Lung J. Cancer biomarkers. Adv Clin Chem. 2015;72:107–70.
[3] Hassanein M, Callison JC, Callaway D, Lane C, Aldrich MC, Grogan EL, Massion PP. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res. 2012;5:992–1006.
[4] Jones JM, Mcgonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006;53:97–101.
[5] Zhao J, Zhao M, Jin B, Yu P, Hu X, Teng Y, et al. Tumor response and survival in patients with advanced non-small cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen. BMC Cancer. 2012;12:330.
[6] Gropp C, Egbrin R, Havemann K. Fibrinogen split products, antiproteases and granulocytic elastase in patients with lung cancer. Eur J Cancer. 1980;16:679–85.
[7] Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol. 1998;28:740–4.
[8] Jiang HG, Li J, Shi SB, Chen P, Ge LP, Jiang Q, et al. Value of fibrinogen and D-dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer. Med Oncol. 2014;31:22.
[9] Kim KH, Park TY, Lee JY, Lee SM, Yin J, Yoo CG, et al. Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci. 2014;29:507–11.
[10] Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis J, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–809.
[11] Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta. 2003;330:31–55.
[12] Guan J, Xiao N, Qiu C, Li Q, Chen M, Zhang Y, et al. Fibrinogen is associated with EGFR mutation status and lymphatic metastasis in non-small cell lung cancer. Oncol Lett. 2019;17:739–46.
[13] Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroen Hepatol. 2007;22:2222–7.
[14] Palumbo JS, Talsmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–85.
[15] Im JH, Fu W, Wang H, Bhatia SK, Hammer DM, Kowalska MA, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004;64:8613–9.
[16] Palumbo JS, Potter JM, Kaplan LS, Talsmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002;62:6966–2.
[17] Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302–9.
[18] Zheng S, Jia Y, Zhao J. Ganoderma lucidum polysaccharides eradicate the blocking effect of fibrinogen on NK cytotoxicity against melanoma cells. Oncol Lett. 2012;3:613–6.
[19] Sheng L, Luo M, Sun X, Lin N, Mao W, Su D. Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer. Int J Cancer. 2013;133:2720–5.
[20] Zhu JF, Cai L, Zhang XW, Wen YS, Xu XD, Rong TH, et al. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases. Chin J Cancer. 2014;33:96.
[21] Zhu LR, Li J, Chen P, Jiang Q, Tang XP. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients. Clin Transl Oncol. 2016;18:178–8.
[22] Wang H, Zhao J, Zhang M, Han L, Wang M, Xingde L. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer. J Cell Physiol. 2018;233:4216–24.
[23] Chen P, Wang C, Cheng B, Nesa EU, Liu Y, Jia Y, et al. Plasma fibrinogen and serum albumin levels (FA score) act as a promising prognostic indicator in non-small cell lung cancer. Onco Targets Ther. 2017;10:3107.
[24] Chen S, Yan H, Du J, Li J, Shen B, Ying H, et al. Prognostic significance of pre-resection albumin/fibrinogen ratio in patients with non-small cell lung cancer: a propensity score matching analysis. Clin Chim Acta. 2018;482:203–8.
[25] Li SQ, Jiang YH, Lin J, Zhang J, Sun F, Gao QF, et al. Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals. Cancer Med. 2018;7:1221–31.

[26] Huang W, Wang S, Zhang H, Zhang B, Wang C. Prognostic significance of combined fibrinogen concentration and neutrophil-to-lymphocyte ratio in patients with resectable non-small cell lung cancer. Cancer Bio Med. 2018;15:88.

[27] Ying J, Zhou D, Gu T, Huang J, Liu H. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. BMC Cancer. 2019;19:288.

[28] Hou C, Jiang F, Ma H, Zhu Q, Wang Z, Zhao B, et al. Prognostic role of preoperative platelet, fibrinogen, and D-dimer levels in patients with non-small cell lung cancer: A multicenter prospective study. Thorac Cancer. 2019;10:304–11.

[29] Liang HG, Gao K, Jia R, Li J, Wang C. Prognostic significance of the combination of preoperative fibrinogen and the neutrophil-lymphocyte ratio in patients with non-small cell lung cancer following surgical resection. Oncol Lett. 2019;17:1435–44.

[30] Song SW, Lee HS, Kim MS, Lee JM, Kim JH, Nam BH, et al. Preoperative serum fibrinogen level predicts postoperative pulmonary complications after lung cancer resection. Ann Thorac Surg. 2006;81:1974–81.

[31] Zhong H, Qian Y, Fang S, Wang Y, Tang Y, Gu W. Prognostic value of plasma fibrinogen in lung cancer patients: a meta-analysis. J Cancer. 2018;9:3904.

[32] Morano MTAP, Mesquita R, Da Silva GPF, Araújo AS, Pinto JMDS, Neto AG, et al. Comparison of the effects of pulmonary rehabilitation with chest physical therapy on the levels of fibrinogen and albumin in patients with lung cancer awaiting lung resection: a randomized clinical trial. BMC Pulm Med. 2014;14:121.

[33] Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest. 1998;101:1372–8.